PE20160195A1 - Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington - Google Patents

Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Info

Publication number
PE20160195A1
PE20160195A1 PE2015002618A PE2015002618A PE20160195A1 PE 20160195 A1 PE20160195 A1 PE 20160195A1 PE 2015002618 A PE2015002618 A PE 2015002618A PE 2015002618 A PE2015002618 A PE 2015002618A PE 20160195 A1 PE20160195 A1 PE 20160195A1
Authority
PE
Peru
Prior art keywords
pridopidine
patient
treatment
high doses
huntington
Prior art date
Application number
PE2015002618A
Other languages
English (en)
Inventor
Esther Lukasiewicz Hagai
Meray Bassan
Teige Wickenberg Anna Kristina Sveinsdotter
Eli Eyal
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of PE20160195A1 publication Critical patent/PE20160195A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion proporciona un metodo de tratamiento de un paciente humano afectado por la enfermedad de Huntington, que comprende la administracion periodica via oral de una composicion farmaceutica que comprende pridopidina o una sal farmaceuticamente aceptable de la misma de tal manera que se administren mas de 135 mg pridopidina al paciente por dia . Esta invencion proporciona ademas un metodo de tratamiento de un paciente humano que padece de enfermedad de Huntington, que comprende administrar oralmente de manera periodica al paciente una composicion farmaceutica que comprende clorhidrato de pridopidina de tal manera que se administren mas de 90 mg de pridopidina al paciente por dia
PE2015002618A 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington PE20160195A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
PE20160195A1 true PE20160195A1 (es) 2016-05-14

Family

ID=52105289

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002618A PE20160195A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE2016002253A PE20170302A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016002253A PE20170302A1 (es) 2013-06-21 2014-06-19 Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington

Country Status (24)

Country Link
US (1) US10322119B2 (es)
EP (1) EP3010506B1 (es)
JP (1) JP2016523862A (es)
KR (1) KR102316933B1 (es)
CN (1) CN105592848A (es)
AU (1) AU2014281414A1 (es)
BR (1) BR112015029918A2 (es)
CA (1) CA2913781C (es)
CL (1) CL2015003690A1 (es)
DK (1) DK3010506T3 (es)
EA (1) EA201690069A1 (es)
ES (1) ES2879631T3 (es)
HK (1) HK1221646A1 (es)
HU (1) HUE054783T2 (es)
IL (1) IL242804B (es)
MX (1) MX2015017307A (es)
PE (2) PE20160195A1 (es)
PH (1) PH12015502691A1 (es)
PL (1) PL3010506T3 (es)
SG (1) SG11201509729YA (es)
TW (1) TW201529069A (es)
UA (1) UA122999C2 (es)
UY (1) UY35624A (es)
WO (1) WO2014205229A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP4049657A1 (en) * 2014-01-22 2022-08-31 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3151507C (en) * 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) * 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CN109952100A (zh) * 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
FI3668509T3 (fi) 2017-08-14 2023-03-14 Prilenia Neurotherapeutics Ltd Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
MX2021015338A (es) * 2019-06-12 2022-01-18 Prilenia Neurotherapeutics Ltd Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
US20220346699A1 (en) * 2019-09-17 2022-11-03 Hoffmann-La Roche Inc. Improvements in Personalized Healthcare for Patients with Movement Disorders
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
HUE029790T2 (hu) 2004-10-13 2017-04-28 Teva Pharmaceuticals Int Gmbh Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2753603B1 (en) * 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
UY34503A (es) * 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
WO2014052935A2 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003608A (es) 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
EP4049657A1 (en) 2014-01-22 2022-08-31 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
HUE060353T2 (hu) 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CA3151507C (en) * 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome

Also Published As

Publication number Publication date
PL3010506T3 (pl) 2021-11-02
PE20170302A1 (es) 2017-03-31
UA122999C2 (uk) 2021-02-03
WO2014205229A1 (en) 2014-12-24
US10322119B2 (en) 2019-06-18
US20140378508A1 (en) 2014-12-25
UY35624A (es) 2015-01-30
DK3010506T3 (da) 2021-07-12
EP3010506B1 (en) 2021-05-12
BR112015029918A2 (pt) 2017-07-25
CA2913781C (en) 2022-05-10
WO2014205229A8 (en) 2015-04-09
EA201690069A1 (ru) 2016-06-30
EP3010506A1 (en) 2016-04-27
CA2913781A1 (en) 2014-12-24
IL242804B (en) 2022-02-01
TW201529069A (zh) 2015-08-01
ES2879631T3 (es) 2021-11-22
JP2016523862A (ja) 2016-08-12
EP3010506A4 (en) 2017-02-08
HUE054783T2 (hu) 2021-09-28
SG11201509729YA (en) 2015-12-30
KR20160055122A (ko) 2016-05-17
CN105592848A (zh) 2016-05-18
AU2014281414A1 (en) 2016-01-21
PH12015502691A1 (en) 2016-03-14
MX2015017307A (es) 2016-08-03
CL2015003690A1 (es) 2016-10-28
HK1221646A1 (zh) 2017-06-09
KR102316933B1 (ko) 2021-10-26

Similar Documents

Publication Publication Date Title
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
EA201370230A1 (ru) Новые ингибиторы rock
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
BR112015009504A2 (pt) inibidores de rock
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal